OPEN

An observational study investigating the CRY1Δ11 variant associated with delayed sleep–wake patterns and circadian metabolic output

Sandra P. Smieszek^{1✉}, Jennifer L. Brzezynski¹, Alyssa R. Kaden¹, Jordan A. Shinn¹, Jingyuan Wang¹, Changfu Xiao¹, Christos Polymeropoulos¹, Tayfun Özçelik² & Mihael H. Polymeropoulos¹

We conducted an observational research study to collect information on sleep–wake patterns from participants with a confirmed status of the cryptochrome circadian clock 1 (*CRY1*) splicing variant, CRY1Δ11 c.1657 + 3A > C, and their controls, defined as wild-type (WT) family members. Altogether, 67 participants were enrolled and completed this study in Turkey, recruited from a list of families with at least one *CRY1*-confirmed member. We measured sleep–wake patterns and metabolic output, specifically time and frequency of bowel movements, for all participants by daily post-sleep diaries over 28 days. The sleep diary measured self-reported bed time, wake time, midpoint of sleep, and latency to persistent sleep (LPS), and accounted for naps and awakenings for religious purposes. Wake time and midpoint of sleep were significantly later in the CRY1Δ11 variant group versus WT, and LPS was significantly greater in participants in the CRY1Δ11 variant group. The mean bed time on all nights of sleep was later in participants with a CRY1Δ11 variant versus WT. Additionally, participants with a CRY1Δ11 variant had significantly affected metabolic outputs, measured by later bowel movements than WT participants. These results demonstrate that, on average, individuals with the studied splicing variant experience pronounced delays in sleep period and circadian-related metabolic processes.

The association of the cryptochrome circadian clock 1 (*CRY1*) gene CRY1Δ11 variant c.1657 + 3A > C with familial delayed sleep–wake phase disorder (DSWPD) was initially described by Patke et al., 2017¹. Acting in a dominant manner, the rs184039278 (G) allele was observed in individuals who had a familial DSWPD, a circadian rhythm disorder affecting the timing of the sleep–wake cycle². DSWPD is the most commonly diagnosed circadian rhythm sleep–wake disorder, with an estimated prevalence of 0.2–10%^{2,3}. It is characterized by a persistent and intractable delay in sleep onset and offset times relative to the societal norm³. Mechanistically, this gain-of-function variant was shown to cause reduced expression of core transcriptional targets, lengthening the period of molecular circadian rhythms¹. The variant leads to enhanced protein activity ultimately increasing affinity for CLOCK and BMAL1 activator proteins¹. Additionally, it has been recently demonstrated that the phenotype caused by the CRY1Δ11 variant (c.1657 + 3A > C) is furthermore due to the deletion of an auto-inhibitory segment of the *CRY1* protein⁴. This rare variant has a global minor allele frequency (MAF) of 0.004, and a higher MAF in the Ashkenazi Jewish population (0.03)⁵.

Moreover, in a reverse phenotyping study, the variant was shown to be associated with attention deficit/hyperactivity disorder (ADHD)⁶. Onat et al. reported a high enrichment of the CRY1Δ11 variant in ADHD patients, specifically in 8 of 62 ADHD patients and in 0 of 369 controls⁶.

We have conducted a rigorous observational research study to collect information on sleep–wake patterns from participants with a confirmed CRY1Δ11 variant status (Fig. 1). The objective of this study was to measure sleep–wake patterns of participants with the CRY1Δ11 variant and controls using a daily sleep diary. Control

¹Vanda Pharmaceuticals Inc., 2200 Pennsylvania Ave. NW, Suite 300E, Washington, DC 20037, USA. ²Department of Molecular Biology and Genetics, Bilkent University, Ankara, Turkey. ✉email: Sandra.Smieszek@vandapharma.com

Figure 1. A. *CRY1* lollipop plot showing the variant of interest, rs184039278, with respect to the domains and location of other known coding variants.

	CRY1Δ11 (time/h)	WT (time/h)	Effect (mins)	p value (Wilcoxon_Rank_Sum)	Cohen's d
Bedtime					
All nights	0:38	0:01	0:37	p value = 0.05	0.41
Wake time					
All nights	8:28	7:44	0:44	p value = 0.01	0.55
Midpoint of sleep					
All nights	4:33	3:53	0:40	p value = 0.01	0.5

Table 1. Summary of Mean Post-Sleep Diary Data. The table displays the bedtime, wake time and midpoint of sleep for variant carriers and controls. Bed time refers to the time when the participant went to bed with intention of going to sleep. Wake time refers to the time the participant woke up. Midpoint refers to the midpoint of sleep.

Figure 2. Boxplots showing significant differences in sleep parameters based on data collected over a period of 28 days (electronic daily diary) for *CRY1*Δ11 variant group (n = 33) compared to WT controls (n = 34). A. Wake Time $p_{\text{wilcoxon}} = 0.02$ (y-axis is time in hours). B. Midpoint $p_{\text{wilcoxon}} = 0.03$ (y-axis is time in hours). C. LPS $p_{\text{wilcoxon}} = 0.001$ (y-axis is time in hours).

or wild-type (WT) participants did not have a *CRY1*Δ11 variant but were family members of participants with a confirmed *CRY1*Δ11 variant. We furthermore aimed to determine the penetrance of the delayed sleep–wake cycle phenotype of a *CRY1*Δ11 variant, as well as assess the impact of the variant on metabolic output.

Results and discussion

The daily sleep diary was used to measure bed time, wake time, midpoint of sleep, and latency to persistent sleep (LPS), and accounted for naps and awakenings for religious purposes. Results showed significant differences in wake time, bed time, and midpoint of sleep on all nights between carriers of a *CRY1*Δ11 variant (n = 33, mean age: 41) and their familial controls (n = 34, mean age: 43), (Table 1). Wake time and midpoint of sleep were both significantly later in the *CRY1*Δ11 variant group than the WT group (Fig. 2A, 40 min difference in wake time: $p_{\text{wilcoxon}} = 0.01$; Fig. 2B, 44 min difference in midpoint of sleep ($p_{\text{wilcoxon}} = 0.01$). The bed time on all nights of sleep (work and free nights) was 37 min later in participants with a *CRY1*Δ11 variant versus WT ($p_{\text{wilcoxon}} = 0.05$) (Fig. 2C). LPS was also significantly greater in participants in the *CRY1*Δ11 variant group, on average 28 min more, resulting in a 12 min difference compared to the WT group, ($p_{\text{wilcoxon}} = 0.001$). Table 1 also shows Cohen's d results showing medium effect size across these three parameters, showing statistical significance. Figure 3 shows the average diary plots for *CRY1*Δ11 variant carriers and their WT familial controls, segregated by free

Figure 3. Visualization of the sleep diary data for free night (without obligation on the next day) and work nights (necessity to work in the morning) for the CRY1 Δ 11 variant group ($n = 33$) compared to WT controls ($n = 34$) sorted by bed time.

and work nights. The delayed-sleep effect is larger on work nights vs. free nights, which is consistent with the inability to induce sleep onset. Furthermore, the variant carriers had a larger individual and average standard deviation (SD) across bed time and wake time (S. Table 1). Importantly, we collected information on nap times, sun exposure, and religious awakenings, and we report no significant difference between the WT and CRY1 groups (S. Figure 2). The WT group included 15/34 females and the CRY1 Δ 11 variant group included 19/33 females. We report no significant difference in the distribution of age across the two groups (S. Figure 2, WT: mean age: 41; CRY1 Δ 11: mean age: 43).

The daily sleep diary was also used to measure the time of a participant's first bowel movement and to capture the metabolic effects of a sleep delay. Participants with a CRY1 Δ 11 variant had significantly later bowel movements than WT participants, delayed on average by 1 h and 31 min (Fig. 4, $p_{\text{wilcoxon}} = 0.002$).

The results of this observational study add to the body of evidence on the association between the CRY1 Δ 11 variant and DSPD. Despite the advantages of using familial controls, it also comes with limitations as those in the same household may be impacted by the sleep patterns of their family members. There are also environmental factors that could further affect the manifested sleep patterns, such as light exposure, level of exercise, daily activities, and caffeine and stimulant consumption. Ultimately based on our study results, 70% of individuals with a confirmed CRY1 Δ 11 variant status manifested the suspected delayed phenotype. The fact that metabolic outputs were also delayed is consistent with the hypothesis and observations on the circadian clock itself. Numerous preclinical studies in gene expression of core clock genes, such as *PER2* and *BMAL1*, show circadian rhythms affecting and coordinating the timing of our metabolic functions within colonic motility coordination sites⁷. Other clinical studies suggest colonic motility follows a rhythm where the majority of individuals have a bowel movement in the morning and, less frequently, a smaller number have their first bowel movement later in the day⁷. In our present study, we used the timing of bowel movement as a marker of metabolic output and, using the other core outputs of clock genes such as sleep onset, tested whether the hypothesis of being delayed is due to the variant of interest. The current study had some limitations that could possibly be addressed in the future studies. The sample of the cohort, even though the largest ever collected in an observational study of this variant, was still relatively small. With Cohen's d ranging between 0.40 and 0.5 we had medium effect size in 3

Figure 4. Mean first bowel movement time by genotype (difference of 1 h and 31 min) obtained from electronic daily diary for CRY1Δ11 variant group ($n = 33$) and WT controls ($n = 34$) $P_{\text{wilcoxon}} = 0.002$ (y-axis is time in hours).

sleep core parameters. Future studies could possibly collect dim light melatonin onset (DLMO) data to further confirm the delayed phenotype.

This observational study provided further insights on sleep characteristics that are most impacted by this highly penetrant CRY1Δ11 variant. The effect of this variant was for the first time described in the context of rigorous 28 day sleep diary—showing its persistent effect on sleep timing as well as its impact on the metabolic output. As individuals carrying this variant may be at greater risk of developing DSPD and comorbidities such as mood disorders, depression and ADHD early detection and intervention may be beneficial. This study laid the framework for future clinical interventional studies aiming to advance carriers of CRY1Δ11.

Methods

Study design. We measured sleep–wake patterns of participants with a CRY1Δ11 variant (rs184039278) and control participants by electronic daily post-sleep diaries for a period of 28 days. The study design is shown in the Supplemental Material (S. Figure 1). After providing informed consent, all 67 participants were asked to complete questionnaires pertaining to demographic information, medical and surgical history, sleep history, concomitant medications, adverse events, and pedigree information. The questionnaires were completed in-person at a site visit or over the phone with a qualified site staff member. The daily post-sleep diary was performed for 28 days over the phone with a qualified site staff member, and the electronic diary was time stamped to ensure responses were recorded in a 24-h window. Participants were asked to restrain use of tobacco, caffeinated drinks and alcohol.

Study participants. Study participants included carriers of a CRY1Δ11 variant ($n = 33$) and controls ($n = 34$), defined as WT family members. Participants were recruited in Turkey from a list of families with at least one CRY1-confirmed member between October 2019 and March 2020. Of the 80 participants invited to participate, 67 were enrolled and completed the observational study. Thirty four (34) of the participants were females, and the mean age was 42.5 years. Participant disposition is shown in the Supplemental Material (S. Figure 1).

Genotyping. Whole blood samples were obtained from participants in a prior study and genomic DNA was extracted. CRY1 c.1657 + 3A > C genotype status was determined by amplifying genomic DNA using hCry1i10F (5'-GTCAACACTTCTGTGAGCCT-3'), hCry1i12R (5'-CAGATGCATGTCTCTTGACC-3'), and restriction digestion analysis. The PCR yielded a 623-bp product of the genomic locus containing exon 11 and was digested with Hpy188I (+ allele: no cut, variant c.1657 + 3A > C: 276 bp + 347 bp).

Statistics. Participants reported their bed time and wake time by daily sleep diary. Daily diaries were collected for each participant for a period of 28 days. Data was summarized by carrier status with means, medians, SDs, minimums, and maximums. The mean was calculated as the average of individual means. Individual mean was calculated as the average for each participant over all nights, work nights, and free nights. For SD, the mean of individual SD was calculated. Analyses were done for both work nights and free nights, defined as a night before work/morning commitment and a night before a free day, respectively. For bedtime/wake time/midnight of sleep, normal distribution assumption was not met. We performed Wilcoxon Rank Sum test. Cohen's d was determined by calculating the mean difference dividing the result by the pooled standard deviation.

Study approval. Participants provided written informed consent before any procedures occurred and were provided a copy of the signed consent form. This study was approved by the institutional ethics committee of Bilkent University (Approval Number: 08-04-2016). All methods were performed in accordance with the relevant guidelines and regulations.

Received: 27 April 2021; Accepted: 20 September 2021
Published online: 11 October 2021

References

1. Patke, A. *et al.* Mutation of the human circadian clock gene CRY1 in familial delayed sleep phase disorder. *Cell* **169**(2), 203–215. e13. <https://doi.org/10.1016/j.cell.2017.03.027> (2017).
2. Nesbitt, A. D. Delayed sleep-wake phase disorder. *J. Thorac. Dis.* **10**(Suppl 1), S103–S111. <https://doi.org/10.21037/jtd.2018.01.11> (2018).
3. Zee, P. C., Attarian, H. & Videnovic, A. Circadian rhythm abnormalities. *Continuum* **19**(1), 132–147. <https://doi.org/10.1212/01.CON.0000427209.21177.aa> (2013).
4. Parico, G. C. G. *et al.* The human CRY1 tail controls circadian timing by regulating its association with CLOCK:BMAL1. *Proc. Natl. Acad. Sci. U.S.A.* **117**(45), 27971–27979. <https://doi.org/10.1073/pnas.1920653117> (2020).
5. Karczewski, K. J., *et al.* Variation across 141,456 human exomes and genomes reveals the spectrum of loss-of-function intolerance across human protein-coding genes. *bioRxiv*. August 531210 (2019). <https://doi.org/10.1101/531210>
6. Onat, O. E. *et al.* Human CRY1 variants associate with attention deficit/hyperactivity disorder. *J. Clin. Investig.* **130**(7), 3885–3900. <https://doi.org/10.1172/JCI135500> (2020).
7. Hoogerwerf, W. A. Role of clock genes in gastrointestinal motility. *Am. J. Physiol. Gastrointest. Liver Physiol.* **299**(3), G549–G555. <https://doi.org/10.1152/ajpgi.00147.2010> (2010).

Acknowledgements

This work was supported by Vanda Pharmaceuticals Inc. We thank Dr. M. W. Young and Dr. A. Patke for valuable discussions. We would like to thank the participants, without whom the project would not have been conducted. We thank the investigator and staff of the study site, including Nezahat Doğan.

Author contributions

S.P.S., J.L.B., C.P., and M.H.P. contributed to the study concept and design. S.P.S., J.W., Z.W. and C.X. contributed to data analysis. S.P.S. wrote the report in collaboration with J.L.B., A.R.K., J.A.S., and T.Ö. T.Ö. conducted the study as an investigator. All authors reviewed and approved the report before submission.

Competing interests

SPS is an employee of Vanda and a stockholder. JLB is an employee of 16 Vanda and a stockholder. ARK is an employee of Vanda and a stockholder. JAS is an employee 17 of Vanda and a stockholder. JW is an employee of Vanda and a stockholder. CX is an employee 18 of Vanda and a stockholder. CP is an employee of Vanda and a stockholder. TÖ is an investigator 19 for Vanda. MHP is Chief Executive Officer of Vanda.

Additional information

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1038/s41598-021-99418-2>.

Correspondence and requests for materials should be addressed to S.P.S.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2021